semaj83/ctmatch_classification huggingface dataset:
Patient description: Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow: Hgb: 13 g/dl WBC: 14000 /mm3 Plt: 300000 /ml AST: 13 U/L ALT: 15 U/L Alk P: 53 U/L Bill total: 0.6 mg/dl Na: 137 mEq/l K: 4 mEq/l Creatinine: 0.5 mg/dl BUN: 10 mg/dl ESR: 120 mm/hr

Clinical trial eligibility criteria: eligible ages (years): 40.0-79.0,  Chronic Pain Hypertension Diuretics Drug Reactions SCS Male or Female, age 40-79 2. Chronic low back pain 3. Permanent spinal cord stimulator implant for chronic pain 4. Stage 1 hypertension (BP 130-139/80-89 mmHg) with ASCVD risk ≥10% 5. Stage 2 hypertension (BP ≥ 140/90 mmHg) 6. Willing to visit research lab (Fairway CTSU) 7. Willing to undergo a blood draw 8. Able to provide written informed consent  Any history of abnormal responses (allergy) to thiazide-type drugs 2. Currently taking any antihypertensive medication 3. Stage 1 hypertension (BP 130-139/80-89 mmHg) with ASCVD risk <10% 4. BP ≥160/100 (these patients should be promptly treated with 2 medications) 5. Secondary hypertension (e.g., aldosteronism, renal artery stenosis) 6. Symptomatic hypotension (weakness or syncope upon standing) 7. Renal failure 8. Diabetes requiring insulin or glucose-lowering drugs 9. History of neurological disease (e.g., dementias, Parkinson's) 10. History of stroke 11. Current diagnosis of cancer 12. Women who are pregnant or planning to become pregnant 13. Any active infection 14. Subject is unwilling or unable to comply with the protocol 15. If currently taking a NSAID, willing to stop for at least 3 days prior to beginning study and throughout study
Patient description: Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow: Hgb: 13 g/dl WBC: 14000 /mm3 Plt: 300000 /ml AST: 13 U/L ALT: 15 U/L Alk P: 53 U/L Bill total: 0.6 mg/dl Na: 137 mEq/l K: 4 mEq/l Creatinine: 0.5 mg/dl BUN: 10 mg/dl ESR: 120 mm/hr

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Fatigue Healthy volunteers or chronically ill patients in stable condition 2. Adults age 18 and above 3. Volunteers who are willing and able to sign the informed consent  Children aged less than 18 years. 2. Subjects participating in another study 3. Subjects who are unable to comply with the study procedures. 4. Patients in an unstable medical condition. 5. Patients who are treated with sedating or stimulant medications 6. Subjects who have taken a dietary supplement within one week of the study initiation 7. Subjects who have drunk or eaten any caffeine-containing beverage or food after 7:00 in the morning of any test day 8. Any reason that, in the opinion of the investigator, may make the subject unfit for this clinical trial
Patient description: Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow: Hgb: 13 g/dl WBC: 14000 /mm3 Plt: 300000 /ml AST: 13 U/L ALT: 15 U/L Alk P: 53 U/L Bill total: 0.6 mg/dl Na: 137 mEq/l K: 4 mEq/l Creatinine: 0.5 mg/dl BUN: 10 mg/dl ESR: 120 mm/hr

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Tuberculosis, Pulmonary Patient 18 years and older Confirmed pulmonary TB (positive Mtb culture or positive polymerase chain reaction (PCR) Mtb-complex) Intended to start on first-line TB treatment HIV negative BMI >17 Written Informed Consent Women of childbearing potential should agree on adequate contraceptives during treatment period and have a negative pregnancy test prior to treatment initiation  Not able to provide informed consent/unable to assimilate study information Concomitant infectious disease that requires treatment Known allergy to rifamycins, isoniazid, pyrazinamide, ethambutol or history of severe sideeffect to any of the drugs Drug-induced inflammatory liver diseases in medical history History of acute liver disease On-going liver disease including hepatitis and elevated transaminase levels >x5 upper normal limit Porphyria Drug-drug interaction between concomitant drugs and rifampicin that could not be bridged by dose-adjustment of the concomitant drug Jaundice Acute gout
Patient description: Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow: Hgb: 13 g/dl WBC: 14000 /mm3 Plt: 300000 /ml AST: 13 U/L ALT: 15 U/L Alk P: 53 U/L Bill total: 0.6 mg/dl Na: 137 mEq/l K: 4 mEq/l Creatinine: 0.5 mg/dl BUN: 10 mg/dl ESR: 120 mm/hr

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Tuberculosis, Pulmonary Tuberculosis Newly diagnosed, uncomplicated, drug-susceptible pulmonary TB 2. Sputum Smear, culture or GenXpert result positive for pulmonary TB 3. Ability to provide written, informed consent prior to trial initiation 4. Male or and non pregnant female participants between 18 and 65 years of age 5. Body mass index 16.0 and 32.0 kg/m2 6. Ability to produce an adequate volume of sputum (approximately 10 -15mL or more estimated overnight production)  Participants known or suspected of having any form of drug resistance TB. 2. Patients co infected with HIV 3. Those with poor general condition where no delay in treatment can be tolerated 4. Evidence of clinically significant metabolic or co morbid medical conditions ; malignancy; or other diseases like history of or current cardiovascular disorder such as heart failure, coronary heart disease, arrhythmia. 5. Known or family history of bleeding disorders. 6. Any renal impairment characterized by serum creatinine clearance of 1.5 x upper limit of normal of the clinical laboratory reference range at screening. 7. Myositis and or Creatinine phosphokinase three times upper limit of normal
Patient description: Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow: Hgb: 13 g/dl WBC: 14000 /mm3 Plt: 300000 /ml AST: 13 U/L ALT: 15 U/L Alk P: 53 U/L Bill total: 0.6 mg/dl Na: 137 mEq/l K: 4 mEq/l Creatinine: 0.5 mg/dl BUN: 10 mg/dl ESR: 120 mm/hr

Clinical trial eligibility criteria: eligible ages (years): 15.0-999.0,  Tuberculosis HIV-1-infection Immuno-Deficiency Patient (and legally designed representative of minor patient) able to correctly understand the trial and to sign the informed consent Aged ≥ 15 years Confirmed HIV-1 infection as documented at any time prior to trial entry per national HIV testing procedures CD4 count ≤ 100 cells/μL Hospitalized for a newly diagnosed TB, defined by Any positive Xpert® MTB/RIF specimen (sputum, urine, pus, other) Or a positive urine lipoarabinomannan (LAM) test Or an abnormal chest X-ray compatible with active TB Initiation of TB drugs for more than 3 days History of TB treatment during the last 6 months
Patient description: Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow: Hgb: 13 g/dl WBC: 14000 /mm3 Plt: 300000 /ml AST: 13 U/L ALT: 15 U/L Alk P: 53 U/L Bill total: 0.6 mg/dl Na: 137 mEq/l K: 4 mEq/l Creatinine: 0.5 mg/dl BUN: 10 mg/dl ESR: 120 mm/hr

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Tuberculosis Stakeholders who consider themselves to be users or potential users of tuberculosis (TB) recommendations will be eligible for participation. For the purposes of this trial, a user is defined as someone who has previously accessed TB guidelines, recommendations or policy advice, and a potential user is someone who plans to access TB guidelines, recommendations, or policy advice in the future Participants may be part of any group that has a stake in TB, including the public, healthcare providers, policymakers, or researchers. Participants may be from either low and middle-income countries (LMIC) or high-income countries (HIC) They may also vary in levels of education and previous TB work experience  Individuals involved in eTB catalogue development
Patient description: Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow: Hgb: 13 g/dl WBC: 14000 /mm3 Plt: 300000 /ml AST: 13 U/L ALT: 15 U/L Alk P: 53 U/L Bill total: 0.6 mg/dl Na: 137 mEq/l K: 4 mEq/l Creatinine: 0.5 mg/dl BUN: 10 mg/dl ESR: 120 mm/hr

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Tuberculosis, Pulmonary years of age or older Informed Consent Form signed Unwell, suspected to have TB or pneumonia  Currently receiving TB treatment On TB treatment past 30 days or more, or last dose less than 1 month before enrolment
Patient description: Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow: Hgb: 13 g/dl WBC: 14000 /mm3 Plt: 300000 /ml AST: 13 U/L ALT: 15 U/L Alk P: 53 U/L Bill total: 0.6 mg/dl Na: 137 mEq/l K: 4 mEq/l Creatinine: 0.5 mg/dl BUN: 10 mg/dl ESR: 120 mm/hr

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Tuberculosis, Pulmonary Is willing and able to give informed consent to participate in the trial treatment and follow-up (signed or witnessed consent if the patient is illiterate). 2. Is aged 18-65 years. 3. Chest X-ray showed that there were active tuberculosis foci in the lungs with one of the following cases: (1) sputum specimens (or sputum and bronchial lavage fluid) were 2+ once or 1+ twice ; (2) sputum smear positive and sputum X-pert positive. 4. Newly diagnosed cases receiving anti-TB treatment for less than one month. 5. No other immune preparations （such as: thymosin，IFN-y，BCG-PSN，Mycobacterium vaccae，Utilins，lentinan ）were used in the past 3 months. 6. the urine analysis of Women of childbearing age are negative and agree to use the efficient contraception during the study period  Has a known allergy to any drug of treatment regimens. 2. There are serious complications or impaired renal function (serum creatinine is 1.5 times higher than the normal limit) or impaired liver function (ALT or AST levels are 3 times higher than the normal limit); hemoglobin is less than 7.0g/dl. Platelets less than 50x109/L. 3. Complication with Diabetic. 4. The screening diagnosis was isoniazid resistance or rifampin resistance 5. There are serious cardiovascular diseases, such as heart failure, hypertension, arrhythmia or post myocardial infarction state. 6. Is known to be pregnant or breast-feeding. 7. Karnofsky score is less than 50%. 8. Is taking any clinical trial in the past 3 months. 9. Is critically ill, and in the judgment of the investigator, not fit for the study or unlikely to complete the full course of study. 10. HIV is positive or AIDS patients. 11. Has Non tuberculous mycobacterial lung disease. 12. Merge with extra pulmonary tuberculosis
Patient description: Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow: Hgb: 13 g/dl WBC: 14000 /mm3 Plt: 300000 /ml AST: 13 U/L ALT: 15 U/L Alk P: 53 U/L Bill total: 0.6 mg/dl Na: 137 mEq/l K: 4 mEq/l Creatinine: 0.5 mg/dl BUN: 10 mg/dl ESR: 120 mm/hr

Clinical trial eligibility criteria: eligible ages (years): 18.0-85.0,  Cough ILD Pulmonary Disease Pulmonary Fibrosis Individuals will be included if having confirmed diagnosis of any ILD by a physician (as per Canadian Thoracic Society's guideline for evaluating patients with fibrotic interstitial lung disease) and a chronic cough lasting more than 8 weeks in duration  self-reports of moderate or large sputum production effective or suspected exacerbation of the respiratory condition in the past month upper respiratory tract infection in the past month use of angiotensin-converting enzyme inhibitor medication changes in the prescribed medication in the previous month evidence of traction bronchiectasis in the HRCT evidence of other medical conditions that prevent performance of an exercise training program unable to read or speak in English / unable to provide informed consent
Patient description: Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow: Hgb: 13 g/dl WBC: 14000 /mm3 Plt: 300000 /ml AST: 13 U/L ALT: 15 U/L Alk P: 53 U/L Bill total: 0.6 mg/dl Na: 137 mEq/l K: 4 mEq/l Creatinine: 0.5 mg/dl BUN: 10 mg/dl ESR: 120 mm/hr

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Tuberculosis, Pulmonary Tuberculosis, Multidrug-Resistant Bacterial Infections Mycobacterial Infection Patient starting an MDR-TB treatment or within the first 4 weeks after treatment initiation and before culture conversion Rifampicin resistant M. tuberculosis detected in sputum using a nucleic acid amplification test New case of TB or re-treatment Can give informed consent at the point of recruitment Contactable (residing in the area covered by participating TB centres and possessing a landline or a mobile phone) Willing to participate for the entire course of the treatment and extensive follow-up  Age <18 years old Anti-MDR-TB therapy within 6 months prior to the start date of the current treatment cycle HIV infection Non-adherent patient with frequent interruptions Patient in custodianship or guardianship Late criterion: no positive cultures at and within the first 3 months of treatment
Patient description: Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow: Hgb: 13 g/dl WBC: 14000 /mm3 Plt: 300000 /ml AST: 13 U/L ALT: 15 U/L Alk P: 53 U/L Bill total: 0.6 mg/dl Na: 137 mEq/l K: 4 mEq/l Creatinine: 0.5 mg/dl BUN: 10 mg/dl ESR: 120 mm/hr

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Non-small Cell Lung Cancer Pancreatic Cancer Colorectal Cancer Prostate Cancer Breast Cancer Ovarian Cancer Loss of Appetite Fatigue Cachexia Anorexia Key Documented diagnosis of non-small cell lung, pancreatic, colorectal, prostate, breast or ovarian cancer which, in the treating oncologist's assessment, is considered incurable Anorexia as defined by a score of ≤5 in the Cancer-Related Cachexia Symptom Assessment Appetite 7-day recall scale Meets any 1 of the following at Randomization Not currently receiving antineoplastic therapy On third line systemic antineoplastic therapy Receiving chemotherapy or immunotherapy treatment which is considered to be without curative intent On a stable regimen of systemic antineoplastic therapy Signed informed consent. Key  Other forms of cancer not listed in Criterion for which treatment has been received in the past 6 months Receiving tube feedings or parenteral nutrition at the time of Screening or Randomization Current active reversible causes of decreased food intake Current, severe gastrointestinal disease Participants with known symptomatic brain metastases requiring steroids Active uncontrolled bacterial, fungal, or viral infection, including HBV, HCV. Confirmed positive test for HIV Elevated blood pressure uncontrolled by medications inadequate renal and liver function Women who are pregnant or breast-feeding